Combined Analysis of Serum Alpha-Fetoprotein and MAGE-A3-Specific Cytotoxic T Lymphocytes in Peripheral Blood for Diagnosis of Hepatocellular Carcinoma

Table 2

Diagnostic performance of frequency of MAGE-A3-specific CTLs and serum AFP singly or in combination for HCC stratified by TNM and clinical stages.

TNM stage	T1N0M0	T2N0M0	T3aN0M0	T3bN0M0	T4N0M0	AnyTN1M0	AnyTanyNM1	Total cases
Clinical stage	I	II	IIIA	IIIB	IIIC	IVA	IVB
HCC, 𝑁 (%)	50 (58.8)	15 (17.7)	10 (11.8)	3 (3.5)	1 (1.2)	3 (3.5)	3 (3.5)	85 (100)
MAGE-A3^+ CTL ≥ 0.67%	36 (72.0%)	11 (73.3%)	4 (40.0%)	1 (33.3%)	0 (0%)	1 (33.3%)	1 (33.3%)	54 (63.5%)
AFP ≥ 200 ng/mL	15 (30.0%)	4 (26.7%)	4 (40.0%)	2 (66.7%)	0 (0%)	1 (33.3%)	1 (33.3%)	27 (31.8%)
MAGE-A3^+ CTL ≥ 0.67% or AFP ≥ 200 ng/mL	42 (84.0%)	12 (80.0%)	5 (50.0%)	2 (66.7%)	0 (0%)	2 (66.7%)	2 (66.7%)	65 (76.5%)